CN111647005A - Barosavir new crystal form and preparation method thereof - Google Patents
Barosavir new crystal form and preparation method thereof Download PDFInfo
- Publication number
- CN111647005A CN111647005A CN202010541268.1A CN202010541268A CN111647005A CN 111647005 A CN111647005 A CN 111647005A CN 202010541268 A CN202010541268 A CN 202010541268A CN 111647005 A CN111647005 A CN 111647005A
- Authority
- CN
- China
- Prior art keywords
- degrees
- crystal form
- baroxavir
- solid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a plurality of new crystal forms of Baloxavir (Baloxavir marboxil, a formula I) and a preparation method thereof. Compared with the prior art, the novel crystal form prepared by the invention has the advantages of good solubility, small hygroscopicity, stable process, strong operability, high yield, good reproducibility of preparation, stable crystal form, suitability for medicine development and the like.
Description
Technical Field
The invention relates to the field of chemical medicine, in particular to a novel baroxavir crystal form for resisting influenza and a preparation method thereof.
Background
Barosavir (Baloxavir marboxil, shown in formula I) is discovered by Japanese salt-sense pharmacy (Shionogi Co), developed together with Roche (Roche), and is approved by the FDA for treating influenza A and B viruses in 2018, 10 and 24 days, and is the first anti-influenza drug approved by the FDA and using a new mechanism. The structure of the drug molecule is shown as follows:
so far, only the original patent WO2018030463A1 reports the crystal form I, the crystal form II and the crystal form III of the crystal form of the baroxavir.
The X-ray powder diffraction patterns of the crystal form I, the crystal form II and the crystal form III disclosed by the patent are as follows:
in addition, the patent discloses that the X-ray powder diffraction of the Barosavir crystal form I has characteristic peaks at 2theta values of 8.6 +/-0.2 degrees, 14.1 +/-0.2 degrees, 17.4 +/-0.2 degrees, 20.0 +/-0.2 degrees, 24.0 +/-0.2 degrees, 26.3 +/-0.2 degrees, 29.6 +/-0.2 degrees and 35.4 +/-0.2 degrees. However, the characteristic peaks of the disclosed form I are not completely consistent with the spectrum.
Through research, the new crystal forms of the baroxavir are obtained, namely the crystal forms V, VII, VIII, IX, X, XI and XII.
Drawings
Figures 1 and 2 provide XRPD and DSC diagrams, respectively, of crystalline balosavir form v.
Figures 3 and 4 provide XRPD and DSC/TGA plots, respectively, for crystalline form vii of baclovir.
Figures 5 and 6 provide XRPD and DSC/TGA plots, respectively, of crystalline form viii of baloxavir.
Figures 7 and 8 provide an XRPD pattern and DSC/TGA pattern, respectively, of crystalline form ix of baroxavir.
Figures 9 and 10 provide XRPD and DSC diagrams, respectively, of balosavir form x.
Figures 11 and 12 provide an XRPD pattern and a DSC pattern, respectively, of barcosivir form xi.
Figures 13 and 14 provide XRPD and DSC/TGA plots of 1:2 barcol oxavir azomethylpyrrolidone solvate, xii, respectively.
Disclosure of Invention
The invention aims to provide a plurality of new baroxavir crystal forms and a preparation method of each crystal form. These crystalline forms can be produced using the methods described herein and are substantially free of other crystalline forms. The term "substantially free" means that the content of the other form is 10% or less, preferably 8%, 5%, 4%, 3%, 2%, 1%, 0.5% or less.
The crystal form can be analyzed by X-ray powder diffraction (XRPD), Differential Scanning Calorimetry (DSC) spectrum, thermogravimetric analysis (TGA) and nuclear magnetic resonance hydrogen spectrum (X-ray powder diffraction-induced diffraction (XRPD) (XRPD)), and the like1H NMR) was performed.
It is an object of the present invention to provide crystalline form v of balosavir.
The crystal form V of the baroxavir provided by the invention is characterized in that characteristic peaks exist at 2theta values of 8.66 +/-0.2 degrees, 9.02 +/-0.2 degrees, 17.96 +/-0.2 degrees, 22.48 +/-0.2 degrees, 24.54 +/-0.2 degrees and 31.64 +/-0.2 degrees in an XRPD pattern.
Further, the crystal form v of baroxavir provided by the invention is characterized in that the XRPD pattern also has characteristic peaks at 2 θ values of 4.60 ± 0.2 °, 17.50 ± 0.2 °, 19.04 ± 0.2 °, 20.46 ± 0.2 °, 21.46 ± 0.2 °, 28.20 ± 0.2 ° and 30.26 ± 0.2 °.
Further, the present invention provides crystalline form v of baroxavir further characterized by an XRPD pattern substantially in accordance with figure 1.
Further, the present invention provides crystalline form v of baroxavir characterized by an endothermic peak at about 239.1 ℃ upon heating, which DSC profile substantially corresponds to figure 2.
It is another object of the present invention to provide a process for the preparation of crystalline form v of basosavir.
Furthermore, the preparation method of the crystal form V of the baroxavir is characterized by comprising the following steps:
(1) adding the solid of the baroxavir into a mixed solvent of acetonitrile and water;
(2) heating to dissolve, and stirring;
(3) cooling to room temperature, and standing;
(4) stirring at room temperature, filtering, and collecting the solid to obtain the crystal form V.
The mixed solvent of acetonitrile and water in the step (1) is characterized in that the ratio of acetonitrile to water is preferably (8-12): 1, more preferably 10: 1.
In the step (2), the dissolving temperature is preferably 55-65 ℃, and more preferably 60 ℃.
Another object of the present invention is to provide a crystalline form vii of baroxavir.
The crystal form VII of the baroxavir provided by the invention is characterized in that characteristic peaks are provided at 2theta values of 4.22 +/-0.2 degrees, 8.34 +/-0.2 degrees, 20.66 +/-0.2 degrees, 22.92 +/-0.2 degrees, 24.84 +/-0.2 degrees and 33.32 +/-0.2 degrees in an XRPD pattern.
Furthermore, the crystal form VII of the baroxavir provided by the invention is characterized in that the XRPD pattern also has characteristic peaks at 2theta values of 8.98 +/-0.2 degrees, 16.52 +/-0.2 degrees, 26.72 +/-0.2 degrees, 29.08 +/-0.2 degrees and 31.66 +/-0.2 degrees.
Further, the present invention provides crystalline form vii of baroxavir which is further characterized by an XRPD pattern substantially in accordance with fig. 3.
Further, the invention provides a crystalline form VII of Barosavir which is characterized by an endothermic peak at about 236.7 ℃ upon heating and which has a DSC/TGA profile substantially in accordance with FIG. 4.
Another object of the present invention is to provide a process for the preparation of crystalline balosavir form vii.
Furthermore, the preparation method of the crystal form VII of the baroxavir is characterized by comprising the following steps:
(1) dissolving a solid of baroxavir in tetrahydrofuran;
(2) and cooling, separating out crystals, and filtering to obtain a solid, namely the crystal form VII.
In the step (1), the dissolving temperature is preferably 45-55 ℃, and more preferably 50 ℃.
In the step (2), the crystallization temperature is preferably-15 to-25 ℃, and more preferably-20 ℃.
It is another object of the present invention to provide a crystalline form viii of balosavir.
The crystal form VIII of the baroxavir provided by the invention is characterized in that characteristic peaks are provided at 2theta values of 8.66 +/-0.2 degrees, 9.06 +/-0.2 degrees, 10.04 +/-0.2 degrees, 10.70 +/-0.2 degrees, 20.00 +/-0.2 degrees, 20.50 +/-0.2 degrees, 21.50 +/-0.2 degrees, 22.52 +/-0.2 degrees, 23.42 +/-0.2 degrees, 24.58 +/-0.2 degrees, 25.64 +/-0.2 degrees, 29.12 +/-0.2 degrees and 31.66 +/-0.2 degrees in an XRPD pattern.
Further, the crystalline form viii of baroxavir provided by the present invention is further characterized by having characteristic peaks at 2 θ values of 4.42 ± 0.2 °, 11.74 ± 0.2 °, 17.14 ± 0.2 °, 18.04 ± 0.2 °, 19.62 ± 0.2 °, 27.56 ± 0.2 °, and 34.54 ± 0.2 ° in the XRPD pattern.
Further, the present invention provides crystalline form viii of balosavir which is further characterized by an XRPD pattern substantially in accordance with fig. 5.
Further, the invention provides a crystalline form viii of balosavir characterized by a small endothermic peak at around 71.4 ℃ due to acetonitrile solvent residue, and an endothermic peak at around 238.4 ℃ upon heating, and having a DSC/TGA profile substantially in accordance with that of fig. 6.
It is another object of the present invention to provide a process for the preparation of crystalline form viii of baloxavir.
Furthermore, the preparation method of the Barosavir crystal form VIII is characterized by comprising the following steps of:
(1) adding the solid of the baroxavir into a mixed solvent of acetonitrile and water;
(2) heating to dissolve, and stirring;
(3) cooling to room temperature, and standing until crystals are separated out;
(4) filtering and drying to obtain solid crystal form VIII.
The mixed solvent of acetonitrile and water in the step (1) is characterized in that the ratio of acetonitrile to water is preferably (8-12): 1, more preferably 10: 1.
In the step (2), the dissolving temperature is preferably 55-65 ℃, and more preferably 60 ℃.
It is another object of the present invention to provide a crystalline form IX of baroxavir.
The crystal form IX of the baroxavir provided by the invention is characterized in that characteristic peaks are provided at 2theta values of 9.10 +/-0.2 degrees, 18.04 +/-0.2 degrees, 22.54 +/-0.2 degrees, 24.56 +/-0.2 degrees and 31.70 +/-0.2 degrees in an XRPD pattern.
Further, the invention provides a crystal form IX of baroxavir, which is characterized in that the XRPD pattern also has characteristic peaks at 2theta values of 4.64 +/-0.2 degrees, 20.52 +/-0.2 degrees, 26.26 +/-0.2 degrees, 26.66 +/-0.2 degrees, 28.22 +/-0.2 degrees and 30.32 +/-0.2 degrees.
Further, the present invention provides crystalline form ix of baroxavir further characterized in that the XRPD pattern thereof is substantially in accordance with fig. 7.
Further, the present invention provides a crystalline form ix of baroxavir characterized by the appearance of an endothermic peak near 237.9 ℃ upon heating, the DSC/TGA diagram substantially corresponding to figure 8.
Another object of the present invention is to provide a process for the preparation of crystalline form ix of baroxavir.
Furthermore, the invention provides a preparation method of the crystal form IX of the baroxavir, which is characterized by comprising the following steps:
(1) adding the solid of the baroxavir into a mixed solvent of acetonitrile and water;
(2) heating to dissolve, and stirring;
(3) dropwise adding water under stirring;
(4) cooling to room temperature, stirring, filtering, and drying the solid to obtain crystal form IX.
The mixed solvent of acetonitrile and water in the step (1) is characterized in that the ratio of acetonitrile to water is preferably (8-12): 1, more preferably 10: 1.
In the step (2), the dissolving temperature is preferably 65-75 ℃, and more preferably 70 ℃.
It is a further object of the present invention to provide a crystalline form x of baroxavir.
The crystal form X of the baroxavir provided by the invention is characterized in that characteristic peaks exist at 2theta values of 4.36 +/-0.2 degrees, 8.44 +/-0.2 degrees, 8.96 +/-0.2 degrees, 20.44 +/-0.2 degrees, 22.54 +/-0.2 degrees, 24.42 +/-0.2 degrees and 26.72 +/-0.2 degrees in an XRPD pattern.
Further, the invention provides a crystalline form x of baroxavir which is characterized by having characteristic peaks in the XRPD pattern at 2 θ values of 17.66 ± 0.2 °, 20.76 ± 0.2 °, 22.96 ± 0.2 °, 28.42 ± 0.2 °.
Further, the present invention provides crystalline form x of baroxavir further characterized by an XRPD pattern substantially in accordance with figure 9.
Further, the present invention provides crystalline form x of baroxavir characterized by an endothermic peak at about 223.5 ℃ upon heating, the DSC diagram of which is substantially in accordance with figure 10.
It is another object of the present invention to provide a process for the preparation of crystalline form x of baroxavir.
Furthermore, the preparation method of the crystal form X of the baroxavir is characterized by comprising the following steps:
(1) dissolving a solid of baroxavir in tetrahydrofuran;
(2) concentrating until solid is separated out;
(3) cooling, and dripping water;
(4) the solid obtained by filtering is the crystal form X.
In the step (2), the concentration temperature is preferably 40-45 ℃, and more preferably 40 ℃.
In the operation of the step (3), the dropping temperature is preferably 15-25 ℃, and more preferably 20 ℃.
It is another object of the invention to provide crystalline form xi of baloxavir.
The crystalline form XI of the baroxavir provided by the invention is characterized in that characteristic peaks are provided at 2theta values of 9.10 +/-0.2 degrees, 9.44 +/-0.2 degrees, 17.82 +/-0.2 degrees, 18.40 +/-0.2 degrees, 19.44 +/-0.2 degrees, 20.94 +/-0.2 degrees, 21.94 +/-0.2 degrees, 22.84 +/-0.2 degrees and 24.94 +/-0.2 degrees in an XRPD diagram.
Furthermore, the crystal form XI of the baroxavir provided by the invention is characterized in that the XRPD pattern also has characteristic peaks at 2theta values of 4.88 +/-0.2 degrees, 11.16 +/-0.2 degrees, 15.32 +/-0.2 degrees, 19.76 +/-0.2 degrees, 26.04 +/-0.2 degrees and 28.54 +/-0.2 degrees.
Further, the invention provides crystalline form xi of baroxavir which is characterized in that the XRPD pattern is substantially in accordance with fig. 11.
Furthermore, the crystal form XI of the baroxavir provided by the invention is characterized in that an endothermic peak appears when the crystal form XI is heated to 226.0 ℃, and a DSC chart of the crystal form XI is basically consistent with that of figure 12.
Another object of the invention is to provide a process for the preparation of baroxavir form xi.
Furthermore, the preparation method of the baroxavir crystal form XI provided by the invention is characterized by comprising the following steps:
(1) dissolving the crystalline form X solid of the baroxavir in a mixed solvent of acetonitrile and water;
(2) stirred and filtered to obtain solid form XI.
The mixed solvent of acetonitrile and water in the step (1) is characterized in that the ratio of acetonitrile to water is preferably (0.9-1.1): 1, more preferably 1: 1.
In the operation of the step (2), the stirring temperature is preferably 23-28 ℃, and more preferably 25 ℃.
It is another object of the invention to provide a 1:2 balsalavir azomethylpyrrolidone solvate xii.
The 1:2 baroxavir azomethylpyrrolidone solvate XII provided by the invention is characterized in that the XRPD pattern thereof has characteristic peaks at 2theta values of 8.66 +/-0.2 degrees, 9.06 +/-0.2 degrees, 10.04 +/-0.2 degrees, 10.70 +/-0.2 degrees, 20.00 +/-0.2 degrees, 20.50 +/-0.2 degrees, 21.50 +/-0.2 degrees, 22.52 +/-0.2 degrees, 23.42 +/-0.2 degrees, 24.58 +/-0.2 degrees, 25.64 +/-0.2 degrees, 29.12 +/-0.2 degrees and 31.66 +/-0.2 degrees.
Furthermore, the 1:2 baroxavir azomethine pyrrolidone solvate XII provided by the invention is further characterized in that the XRPD pattern also has characteristic peaks at 2theta values of 4.42 +/-0.2 degrees, 11.74 +/-0.2 degrees, 17.14 +/-0.2 degrees, 18.04 +/-0.2 degrees, 19.62 +/-0.2 degrees, 27.56 +/-0.2 degrees and 34.54 +/-0.2 degrees.
Further, the present invention provides a 1:2 balsalavir azomethylpyrrolidone solvate, XII, which is characterized in that the XRPD pattern substantially corresponds to that of FIG. 13.
Furthermore, the invention provides a 1:2 balsalavir azomethylpyrrolidone solvate XII which is characterized in that an endothermic peak appears when heated to a temperature of about 73.5 ℃ and 125.65 ℃, and the DSC/TGA chart thereof is substantially in accordance with that of FIG. 14.
It is another object of the invention to provide a process for the preparation of a 1:2 balsalavir azomethylpyrrolidone solvate, XII.
Further, the invention provides a preparation method of a 1:2 balosavir nitrogen methyl pyrrolidone solvate XII, which is characterized by comprising the following steps:
(1) adding the baroxavir solid to the N-methylpyrrolidone;
(2) heating to dissolve and clear;
(3) and (4) performing rotary evaporation and drying to obtain a solid, namely a solvate XII.
In the step (2), the dissolving temperature is preferably 60-70 ℃, and more preferably 65 ℃.
In the operation of the step (3), the rotary evaporation temperature is preferably 80-100 ℃.
The invention provides several new Barrosavir crystal forms and a preparation method thereof, and the obtained crystal forms have the advantages of good solubility, small hygroscopicity, stable process, strong operability, high yield, good reproducibility of preparation, stable crystal forms, suitability for medicine development and the like.
Detailed Description
The invention will be further illustrated by the following specific examples, which are not intended to limit the scope of the invention. The skilled person can make modifications to the preparation method and the apparatus used within the scope of the claims, and such modifications should also be considered as the protection scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
In the examples below, unless otherwise indicated, the test procedures described are generally carried out according to conventional conditions or manufacturer's conditions; the raw materials and the reagents can be obtained by a commercially available mode.
Example 1
Preparation of Barosavir form V
571mg of baloxavir was added to 2.5mL of acetonitrile: water 10: 1(v: v), heating to 60 ℃, dissolving, stirring for 70min, cooling to room temperature, standing for 45.5 hours, stirring, filtering, and collecting a solid to obtain a crystal form V. The XRPD pattern is shown in figure 1, and the DSC pattern is shown in figure 2. The crystal form can be stably stored for 3 to 6 months under the closed condition at room temperature.
Example 2
Preparation of Barosavir crystal form VII
Adding 497mg of balosavir into 10mL of tetrahydrofuran, heating to 50 ℃ for dissolving, stirring for 30min, cooling to-20 ℃, storing for 24 days, filtering, and collecting solid to obtain the crystal form VII. The XRPD pattern is shown in FIG. 3, and the DSC/TGA pattern is shown in FIG. 4. The crystal form can be stably stored for 3 to 6 months under the closed condition at room temperature.
Example 3
Preparation of Barosavir crystal form VIII
501mg of baloxavir was added to 2mL of acetonitrile: water 10: 1(v: v), heating to 60 ℃ to dissolve, stirring for 30min, cooling to room temperature, standing for 17 days, filtering, and drying to obtain the crystal form VIII. The XRPD pattern is shown in FIG. 5, and the DSC/TGA pattern is shown in FIG. 6. The crystal form can be stably stored for 3 to 6 months under the closed condition at room temperature.
Example 4
Preparation of Barosavir crystal form IX
7.99g of baloxavir were added to 32mL of acetonitrile: water 10: 1(v: v), heating to 70 ℃ for dissolving, stirring for 40min, adding 40mL of water, stirring for 5min at 70 ℃, cooling to room temperature, stirring for 85min, filtering, collecting solids, and drying to obtain crystal form IX. The XRPD pattern is shown in FIG. 7, and the DSC/TGA pattern is shown in FIG. 8. The crystal form can be stably stored for 3 to 6 months under the closed condition at room temperature.
Example 5
Preparation of Barosavir form X
Dissolving 5g of baroxavir solid in 50mL of tetrahydrofuran, concentrating at 45 ℃ until solid is separated out, cooling to 20 ℃, dropwise adding 23g of water, filtering, washing a filter cake with 10mL of water, collecting the filter cake, and drying to obtain the crystal form X. The XRPD pattern is shown in FIG. 9, and the DSC pattern is shown in FIG. 10. The crystal form can be stably stored for 3 to 6 months under the closed condition at room temperature.
Example 6
Preparation of Barosavir form XI
30mg of balosavir form x was added to 0.4mL of acetonitrile: water 1: 1(v: v), stirring at 25 ℃ for 3 days, filtering, collecting the solid, and drying to obtain the crystalline form XI. The XRPD pattern is shown in FIG. 11, and the DSC pattern is shown in FIG. 12. The crystal form can be stably stored for 3 to 6 months under the closed condition at room temperature.
Example 7
1:2 preparation of Barosavir Azymethylpyrrolidone solvate XII
Adding 501mg of baroxavir into 15mL of N-methyl pyrrolidone, heating to 65 ℃ to dissolve, stirring for 10min, carrying out rotary evaporation at 85 ℃ for 95min, carrying out rotary evaporation at 85 ℃ for 25min by using an oil pump, carrying out rotary evaporation at 100 ℃ for 80min by using an oil pump, and drying to obtain a 1:2 baroxavir N-methyl pyrrolidone solvate XII. The XRPD pattern is shown in FIG. 13, and the DSC/TGA pattern is shown in FIG. 14. The crystal form can be stably stored for 3 to 6 months under the closed condition at room temperature.
1H NMR (DMSO) 7.40-7.42(2H, m),7.22-7.24(1H, d, J-7.8 Hz),7.13-7.17(1H, m),7.08-7.10(1H, m),7.00-7.02(1H, m),6.83-6.87(1H, m),5.72-5.74(3H, m),5.66-5.67(1H, m), 5.40-5.44(1H, m),4.39-4.67(2H, m),3.98-4.08(2H, m),3.73 (3H, s),3.67-3.71(1H, m),3.44-3.47(1H, t, J-10.5 Hz), 3.28-3.30(5H, m, 3.25, 3.91-2H, m), NMP (1H, 2H, m), NMP, NM, 1.86-1.94(5H, m, NMP methylene).
The above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (12)
1. A crystal form VII of Barosavir is characterized in that an X-ray powder diffraction pattern of the crystal form VII has characteristic peaks at 2theta values of 4.22 +/-0.2 degrees, 8.34 +/-0.2 degrees, 20.66 +/-0.2 degrees, 22.92 +/-0.2 degrees, 24.84 +/-0.2 degrees and 33.32 +/-0.2 degrees.
2. The crystalline form VII of claim 1, characterized by an X-ray powder diffraction pattern substantially in accordance with fig. 3.
3. The preparation method of the crystal form VII according to claims 1 and 2, characterized by comprising the following steps:
(1) dissolving a solid of baroxavir in tetrahydrofuran;
(2) and cooling, separating out crystals, and filtering to obtain a solid, namely the crystal form VII.
4. A crystal form VIII of baroxavir is characterized in that an X-ray powder diffraction pattern of the crystal form VIII has characteristic peaks at 2theta values of 8.66 +/-0.2 degrees, 9.06 +/-0.2 degrees, 10.04 +/-0.2 degrees, 10.70 +/-0.2 degrees, 20.00 +/-0.2 degrees, 20.50 +/-0.2 degrees, 21.50 +/-0.2 degrees, 22.52 +/-0.2 degrees, 23.42 +/-0.2 degrees, 24.58 +/-0.2 degrees, 25.64 +/-0.2 degrees, 29.12 +/-0.2 degrees and 31.66 +/-0.2 degrees.
5. The crystalline form VIII of claim 4 having an X-ray powder diffraction pattern substantially in accordance with FIG. 5.
6. A method for preparing crystalline form VIII according to claims 4 and 5, characterized in that it comprises the following steps:
(1) adding the solid of the baroxavir into a mixed solvent of acetonitrile and water;
(2) heating to dissolve, and stirring;
(3) cooling to room temperature, and standing until crystals are separated out;
(4) filtering and drying to obtain solid crystal form VIII.
7. A crystal form IX of Barosavir is characterized in that an X-ray powder diffraction pattern of the crystal form IX has characteristic peaks at 2theta values of 9.10 +/-0.2 degrees, 18.04 +/-0.2 degrees, 22.54 +/-0.2 degrees, 24.56 +/-0.2 degrees and 31.70 +/-0.2 degrees.
8. A crystalline form IX according to claim 7, characterized in that its X-ray powder diffraction pattern substantially corresponds to that of figure 7.
9. A process for the preparation of crystalline form IX according to claims 7, 8, characterized in that it comprises the following steps:
(1) adding the solid of the baroxavir into a mixed solvent of acetonitrile and water;
(2) heating to dissolve, and stirring;
(3) dropwise adding water under stirring;
(4) cooling to room temperature, stirring, filtering, and drying the solid to obtain crystal form IX.
10. A1: 2 baroxavir azomethylpyrrolidone solvate XII is characterized in that an X-ray powder diffraction pattern thereof has characteristic peaks at 2theta values of 8.66 +/-0.2 degrees, 9.06 +/-0.2 degrees, 10.04 +/-0.2 degrees, 10.70 +/-0.2 degrees, 20.00 +/-0.2 degrees, 20.50 +/-0.2 degrees, 21.50 +/-0.2 degrees, 22.52 +/-0.2 degrees, 23.42 +/-0.2 degrees, 24.58 +/-0.2 degrees, 25.64 +/-0.2 degrees, 29.12 +/-0.2 degrees and 31.66 +/-0.2 degrees.
11. Solvate XII according to claim 10, characterised in that it has an X-ray powder diffraction pattern substantially in accordance with FIG. 13.
12. The process for the preparation of a solvate XII of 1:2 Barosavir azomethylpyrrolidone, according to claims 10 and 11, comprising the steps of:
(1) adding the baroxavir solid to the N-methylpyrrolidone;
(2) heating to dissolve and clear;
(3) and (4) performing rotary evaporation and drying to obtain a solid, namely a solvate XII.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010541268.1A CN111647005A (en) | 2020-06-15 | 2020-06-15 | Barosavir new crystal form and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010541268.1A CN111647005A (en) | 2020-06-15 | 2020-06-15 | Barosavir new crystal form and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111647005A true CN111647005A (en) | 2020-09-11 |
Family
ID=72345609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010541268.1A Withdrawn CN111647005A (en) | 2020-06-15 | 2020-06-15 | Barosavir new crystal form and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111647005A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021057834A1 (en) * | 2019-09-27 | 2021-04-01 | 广东东阳光药业有限公司 | Crystal form of ester compound and preparation method therefor |
| WO2022100395A1 (en) * | 2020-11-12 | 2022-05-19 | 上海迪赛诺生物医药有限公司 | Baloxavir marboxil crystal form d and preparation method therefor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019098259A1 (en) * | 2017-11-17 | 2019-05-23 | 塩野義製薬株式会社 | Pharmaceutical preparation having excellent photostability and drug release properties |
| CN110494141A (en) * | 2016-08-10 | 2019-11-22 | 盐野义制药株式会社 | Pharmaceutical composition containing substituted polycyclic Pyridione derivatives and its prodrug |
| CN111377944A (en) * | 2018-12-25 | 2020-07-07 | 广东东阳光药业有限公司 | Baloxavir marboxil crystal form and preparation method thereof |
-
2020
- 2020-06-15 CN CN202010541268.1A patent/CN111647005A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110494141A (en) * | 2016-08-10 | 2019-11-22 | 盐野义制药株式会社 | Pharmaceutical composition containing substituted polycyclic Pyridione derivatives and its prodrug |
| WO2019098259A1 (en) * | 2017-11-17 | 2019-05-23 | 塩野義製薬株式会社 | Pharmaceutical preparation having excellent photostability and drug release properties |
| CN111377944A (en) * | 2018-12-25 | 2020-07-07 | 广东东阳光药业有限公司 | Baloxavir marboxil crystal form and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021057834A1 (en) * | 2019-09-27 | 2021-04-01 | 广东东阳光药业有限公司 | Crystal form of ester compound and preparation method therefor |
| CN114258395A (en) * | 2019-09-27 | 2022-03-29 | 广东东阳光药业有限公司 | Crystal form of ester compound and preparation method thereof |
| WO2022100395A1 (en) * | 2020-11-12 | 2022-05-19 | 上海迪赛诺生物医药有限公司 | Baloxavir marboxil crystal form d and preparation method therefor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE202018006384U1 (en) | Production of psilocybin, various polymorphic forms, intermediates, formulations and their use | |
| CN111647005A (en) | Barosavir new crystal form and preparation method thereof | |
| WO2024017170A1 (en) | S-(-)-nicotine(-)-dibenzoyl-l-tartrate crystal form, preparation method and use | |
| CN108129385A (en) | A kind of compound quaternary ammonium salt nonlinear optics crystalline state material and preparation method thereof | |
| CN113248439A (en) | Synthesis method of pyrazole disulfide | |
| WO2017177781A1 (en) | Ahu377 crystal forms, and preparation method therefor and use thereof | |
| Frauenhoff et al. | Isolation, characterization, and substitution reactions of the osmium trinuclear triflate complex H2Os3 (CO) 9 (O3SCF3) 2. X-ray crystal structure of the mixed oxyligand cluster (. mu.-H) 2Os3 (CO) 9 (. mu.,. eta. 2-O2CCH3)(. eta. 1-O3SCF3) | |
| CN116874401A (en) | New green thiodicarb synthesis process | |
| CN114773176B (en) | Chlorpheniramine maleate impurity and preparation method and application thereof | |
| CN111138353A (en) | Nicotinate hydrate and preparation method thereof | |
| DE19833913A1 (en) | Process for the preparation of N, N'-carbonyldiazoles | |
| CN106632131A (en) | Hexythiazox and preparation method thereof | |
| CN112939922B (en) | Synthesis method of 1-cyano-6-methylsulfonyl-7-nitro-9H-xanthene-9-ketone | |
| CN112079737B (en) | Preparation method of 1,4,5, 8-tetra (4-n-butylphenylamino) anthraquinone | |
| CA2523854C (en) | Crystals of quinolinecarboxylic acid derivative solvate | |
| CN114773312B (en) | Preparation process of alolol hydrochloride intermediate | |
| CN113861127B (en) | Preparation method of benzothiazole derivative drug molecules | |
| CN112409350B (en) | Preparation method of maleic acid atorvastatin crystal form C | |
| CN114349690B (en) | Synthesis method of doravirine intermediate | |
| CN111620875B (en) | Preparation process of imidazopyrazine compound | |
| CN111233672B (en) | Method for synthesizing nifedipine intermediate by using combined catalyst | |
| DE1695627A1 (en) | Process for the preparation of 3-aminopyrrolidines | |
| CN115894445A (en) | Synthesis method of Voranolan fumarate impurity | |
| CN116589392A (en) | Method for producing thiodicarb by using single solvent and no catalyst | |
| CN117603143A (en) | Synthesis method of oxazine 294 impurity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200911 |